Tissue factor (TF) and its inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies;Stȩżenie czynnika tkankowego i jego inhibitora u chorych na guzy układu moczowego i choroby rozrostowe układu krwiotwórczego

Polski Merkuriusz Lekarski

Volumn 13, Issue 76, 2002, Pages 308-311

  Radziwon, Piotr ^a   Schenk, Joachim F ^a   Mazgajska, Katarzyna ^a   Boczkowska Radziwon, Barbara ^a   Galar, Marzenna ^a   Kłoczko, Janusz ^a   Wojtukiewicz, Marek Z ^a  

^a Regionalne Centrum Krwiodawstwa   (Poland)

Author keywords

Neoplasia; TF; TFPI

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLADDER CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROSTATE HYPERTROPHY; URINARY TRACT TUMOR; ACUTE GRANULOCYTIC LEUKEMIA; BLADDER TUMOR; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; KIDNEY TUMOR; LEUKEMIA; MALE; METABOLISM; URINARY TRACT CANCER;

CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LIPOPROTEINS; MALE; MULTIPLE MYELOMA; PROSTATIC HYPERPLASIA; THROMBOPLASTIN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 17644429096     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bauer K.A. i wsp.: Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood, 1989, 74, 165.
2. Broze G.J. Jr i wsp.: The lipoprotein associated coagulation inhibitor that inhibits the factor VII/tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood, 1988, 71, 335.
3. Broze G.J. i wsp.: Inhibition of factor VIIa/tissue factor by antithrombin III and tissue factor pathway inhibitor. Blood, 1993, 82, 1679.
4. Hack C.E. i wsp.: Role of cytokines in sepsis. Adv. Immunol., 1997, 66, 101.
5. Hamamoto T., Kisiel W.: Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Thromb. Res., 1995, 80, 291-297.
6. Iversen N. i wsp.: Elevated TFPI in malignant disease: Relation to cancer type and hypercoagulation. Br. J. Haematol., 1998, 102, 889.
7. Kakkar A.K, i wsp.: A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis, 1998, 28, 1.
8. Lindahl A.K. i wsp.: Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer, 1992, 70, 2067.
9. Lindahl A.K. i wsp.: High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir. Scand., 1989, 155, 389.
10. Lindahl A.K. i wsp.: Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancerpatients. Blood Coagul. Fibrinolysis, 1991, 2, 713.
11. Lindahl A.K.: Tissue factor pathway inhibitor. Biomedical Progress, 1994, 7, 43.
12. Masys D.R. i wsp.: Activation of human factor VII by activated factors IX and X. Blood, 1982, 60, 1143.
13. Morrissey J.H. i wsp.: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood, 1993, 81, 734.
14. Nagakaki T. i wsp.: Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry, 1991, 30, 10819.
15. Novotny W.F. i wsp.: Plasma antigen levels of the lipoprotein associated coagulation inhibitor In patient samples. Blood, 1991, 78, 387.
16. Novotny W.F. i wsp.: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood, 1988, 72, 2020.
17. Novotny W.F. i wsp.: Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J. Biol. Chem., 1989, 264, 18832.
18. Osterud B., Flaegstad T.: Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavorable prognosis. Thromb. Haemost., 1983, 49, 5.
19. Rapaport S.I., Rao L.V.M.: The tissue factorpathway: How it has become a "Prima Ballerina". Thromb. Haemost., 1995, 4, 7.
20. Rapaport S.I.: Blood coagulation and its alterations in hemorrhagic and thrombotic disorders. West. J. Med., 1993, 158, 153.
21. Sandset P.M. i wsp.: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res., 1988, 50, 803.
22. Shimura M. i wsp.: Plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol., 1996, 52, 165.
23. Takahashi H. i wsp.: Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation - Comparison of its behavior with plasma tissue factor. Thromb. Res., 1995, 80, 339.
24. Tonnesen M.G. i wsp.: Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro. J. Clin. Invest., 1984, 74, 1581.
25. Valentin S. i wsp.: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul. Fibrinolysis, 1993, 4, 713.
26. Velasco F. i wsp.: Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coagul. Fibrin., 1997, 8, 70.
27. Werling R.W. i wsp.: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb. Haemost., 1993, 69, 366.
28. Wojtukiewicz M.Z. i wsp.: Thrombin increases the metastatic potential of tumor cells. Int. J. Cancer, 1993, 54, 793.
29. Wun T.: Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood, 1992, 79, 430.
30. Wun T.C. i wsp.: Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study. J. Biol. Chem., 1990, 265, 16096.